Innovative Diagnostic Platform Abionic’s flagship abioSCOPE® offers rapid, lab-quality diagnostic results at the point-of-care, providing opportunities to expand sales within hospitals, clinics, and emergency services seeking quick and accurate testing solutions.

Award-Winning Credibility Having received prestigious awards such as Swiss MedTech of the Year in 2023, Abionic’s reputation can be leveraged to build trust with potential clients looking for proven, award-winning medical technology solutions.

Strategic Partnerships The company's recent collaboration with Fapon Biotech and LASCCO SA indicates a growing network of strategic alliances that can facilitate entry into new markets or enhance existing offerings, presenting opportunities for cross-selling and joint ventures.

Focus on COVID-19 Solutions Abionic’s development of rapid COVID-19 severity testing tools like cSOFA demonstrates expertise in infectious disease diagnostics, opening avenues for sales in pandemic preparedness, hospital diagnostics, and global health markets.

Growth Potential in Diagnostics Despite current revenue under $1M, Abionic’s innovative platform and recent awards position it for significant growth, making it an attractive target for investments, distribution partnerships, and expansion into new geographic markets or clinical applications.